Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634948 | 0.75 | LMNA (0.36) | ATM | |
| SCHEMBL3635465 | 0.73 | L3MBTL1 (0.37) | ATM | |
| SCHEMBL28321078 | 0.71 | ATM (0.32) | ATM | |
| Hydrochloric Acid SCHEMBL9698155 | 0.71 | L3MBTL1 (0.35) | ATM | |
| SCHEMBL4104348 | 0.71 | ATM (0.36) | ATM | |
| SCHEMBL4109208 | 0.70 | ATM (0.35) | ATM | |
| SCHEMBL4637388 | 0.70 | L3MBTL1 (0.34) | ATM | |
| Carbamic Acid SCHEMBL15206061 | 0.68 | ATM (0.42) | ATM | |
| SCHEMBL25076094 | 0.67 | ALDH1A1 (0.38) | — | |
| SCHEMBL2026585 | 0.66 | L3MBTL1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188276-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-8063085-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1989186-B1 | HYDANTOIN BASED KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | disclosed |
| EP-2234982-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2188276-A1 | SUBSTITUTED HYDANTOINS | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-7612212-B2 | 2-[(S)-2-((S)-2,5-dioxo-4-phenyl-imidazolidin-1-yl)-4-methyl-pentanoylamino]-thiazole-4-carboxylic acid methyl ester; mitogen activated protein/extracellular signal regulated kinase kinase inhibitor; anticarcinogenic agent, cognition activator, nervous and autoimmune system disorders | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7557221-B2 | Substituted hydantoins | HOFFMAN-LA ROCHE INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090170920-A1 | SUBSTITUTED HYDANTOINS | CHEN SHAOQING | 2009-07-02 | — | — | US | disclosed |
| WO-2009080523-A1 | SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | CHEN SHAOQING | 2009-02-19 | — | — | US | disclosed |
| WO-2009021887-A1 | SUBSTITUTED HYDANTOINS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-19 | — | — | WO | disclosed |
| EP-1989186-A1 | HYDANTOIN BASED KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008101840-A1 | COMBINATION OF ERLOTINIB AND MEK-INHIBITORS FOR INHIBITING PROLIFERATION OF TUMOR CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | NIU HUIFENG | 2008-08-28 | — | — | US | disclosed |
| WO-2007096259-A1 | HYDANTOIN BASED KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-20070197617-A1 | Substituted hydantoins | CHEN SHAOQING | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197617-A1 | Substituted hydantoins | HNMT, HRH3, BRAF | ATM 1359/4885 |
| US-20090048452-A1 | (R)-5-[4-(2-Hydroxy-ethoxy)-phenyl]-3-[(S)-1-(6-iodo-1H-benzoimidazol-2-yl)-2-phenyl-ethyl]-imidazolidine-2,4-dione; map kinase inhibitors; antihyperproliferative agents | MAPK1, MAP3K2, MAP3K1 | ATM 1040/4885 |
| US-20090170920-A1 | SUBSTITUTED HYDANTOINS | HNMT, HRH3, BRAF | ATM 1359/4885 |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | MKI67, BRAF, MYC | ATM 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.